Effect of once-weekly semaglutide on the counterregulatory response to hypoglycaemia in people with type 2 diabetes: A randomized, placebo-controlled, double-blind, crossover trial.
Stefan KorsatkoLene JensenMartina BrunnerStefanie Sach-FriedlMaja D TarpAnders G HolstSimon R HellerThomas R PieberPublished in: Diabetes, obesity & metabolism (2018)
Semaglutide treatment did not compromise the counterregulatory glucagon response during experimental hypoglycaemia in people with T2D.